Skip to main content
Premium Trial:

Request an Annual Quote

Klaus Puel, Wolfgang Pieken, Daniel Kisner, David Milligan, Wally Parce, Robert Booth

Premium

Klaus Puel has been appointed CEO and president of oligo and DNA synthesis reagent supplier Proligo, a Boulder, Colo., subsidiary of German company Degussa. Puel replaces Proligo co-founder Wolfgang Pieken, who has stepped down to pursue other business interests, the company said.

Puell joined Proligo in 1999, with the position of senior vice president. Subsequently, he became vice president of E.On, the parent company of Degussa.

 

Lab-on-a-chip company Caliper Technologies has elected Daniel Kisner, its former chief executive officer, as chairman of its board, and David Milligan, its former chairman of the board, as vice chairman. The company also said that Wally Parce, vice president of research, will be stepping down from his position at the end of the year to become a consultant.

 

Robert Booth has been appointed senior vice president of R & D at Celera Genomics. Booth will be in charge of Celera’s drug discovery and development programs. He comes to Celera from Hoffmann-La Roche, where he led the inflammatory and viral diseases business unit, and central R&D at Roche Bioscience. Booth was a member of the global research management team and was recently appointed the head of the global biology team. Before joining Hoffman-LaRoche 13 years ago, Booth spent three years managing research activities at Wellcome Research Laboratories, and four years at Searle Research & Development.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.